Our Research

Discover our recent findings, catch up with news, and review in-depth resources and case studies.

Preventing False Positives: Considerations for the Development of Targeted Methodologies

At Resolian we specialise in the efficient development of highly selective, tailored methods which differentiate between nitrosamines and structurally similar impurities that would otherwise lead to a false positive.
Read more

Unlocking the Power of Ultrasensitive Bioanalysis

🔬 How do you measure complex modality molecules at the lowest possible concentrations? For modern therapies like antibody-drug conjugates (ADCs) and inhzlation drugs, precise bioanalysis at picogram levels is essential to ensure both efficacy and safety. At Resolian, we specialize in ultrasensitive assays that push the boundaries of detection.
Read more

Advancing Immunoassay Method Development and Automation at Resolian

Precision, efficiency, and scientific expertise are essential in today’s fast-moving bioanalytical landscape. At Resolian, we’ve taken a bold step forward—restructuring teams, refining method development processes, and strategically implementing automation to enhance service delivery.
Read more

De-risk Your Drug Development with Resolian’s Polymorph Screening Expertise

Polymorph screening is a process that identifies and characterizes the crystalline forms of a compound, and then selects the best form for development. Assessing and controlling the crystalline form of your material plays a crucial role in all the stages of the product lifecycle.
Read more

Foreign Particulate Matter Solutions for Vaccine Safety

Foreign particulate matter (FPM) in vaccines poses risks to product safety, patient health, and regulatory compliance. With stringent guidelines from agencies like the FDA and EMA, identifying and controlling contaminants is essential to maintaining trust and ensuring safety.
Read more

Oligonucleotide Therapeutics Podcast

Min Meng, Chief Operations Officer at Resolian. The interview focuses on the bioanalysis of oligonucleotide therapeutics, a rapidly evolving area in drug development. Min Meng, with 20+ years of experience in this field, provides valuable insights into the unique challenges and advantages of these therapies.
Read more
Scroll to Top

Oligonucleotide Therapeutics Podcast

In our latest podcast we discuss the bioanalysis of oligonucleotide therapeutics, a growing area in pharmaceutical development. 

Min Meng, a leading expert, explains the different types of oligonucleotides (e.g., ASO, sRNA, PMO), highlighting their unique characteristics compared to small molecule and protein therapeutics.

She details and contrasts the various analytical methods used for their detection and quantification, focusing on the advantages and challenges of liquid chromatography-mass spectrometry (LC-MS relative to other technologies).

Finally, the discussion covers the importance of analysing the lipid nanoparticle delivery systems and the factors contributing to the success or failure of oligonucleotide therapies.

Key Takeaways

Strategic Considerations for Adopting Oligonucleotide Therapies

  • Targeted Therapy:
    Oligonucleotides offer a targeted approach, allowing for scientific design to target specific genes.
  • Potential to Cure Diseases:
    In theory, oligonucleotide therapy can address any disease caused by a mutant gene, provided the target can be reached.
  • Higher Success Rates:
    Unlike small molecule development, which has a reported 5% success rate (doubling to 10% with good biomarkers), oligonucleotide therapies have shown significantly higher success rates around 60%.
  • Increased Investment:
    The high success rates make them an attractive proposition for pharmaceutical companies and investors.
  • Potential Failure Causes:
    While specific reasons are speculative, potential issues include LNP toxicity or immunogenicity. The use of GalNAc delivery systems (an endogenous sugar carrier) may be a way to mitigate LNP-related challenges.

What You Will Learn

By watching this podcast, you will gain insights into:

💡 Targeted Therapies: How oligonucleotides are designed to address specific genes, offering precision in treatment.

💡 Disease Applications: The potential of oligonucleotide therapies to address genetic diseases, provided the target is accessible.

💡 Higher Success Rates: A closer look at how these therapies achieve success rates significantly higher than small molecules.

💡 Industry Growth: Why increased investment is fuelling innovation and expanding the applications of oligonucleotide therapeutics.

This podcast is a must-watch for anyone working in the pharmaceutical industry, drug development, or interested in the future of medicine. Min’s expertise provides a wealth of knowledge on the complexities and exciting potential of oligonucleotide therapeutics.

Fill in the form to access the full episode and discover how these innovative therapies are paving the way for new treatment options!

 

Watch the podcast today

Please enter the required details to watch the podcast.

About Resolian

Our footprint includes five sites on four continents. It starts with our headquarters near Philadelphia, Pennsylvania, includes two labs in the UK, a lab in Chongqing, China, and Brisbane, Australia. Our areas of expertise include bioanalysis for all drug modalities, from conventional small molecules, monoclonal antibodies, peptides, oligonucleotides, and complex biologics like ADCs, AOCs, and biospecific antibodies.

Learn more about our Bioanalytics capabilities here

Zhiyang Zhao, Ph.D.

Chief Scientific Officer

Linkedin

Zhiyang Zhao, Ph.D., serves as Chief Scientific Officer (CSO) at Resolian. Dr. Zhao has over 30 years of pharmaceutical industry experience with special focus on drug metabolism and bioanalysis of small and large molecules in drug discovery and development. Dr. Zhao has previously held positions at Pfizer, GlaxoSmithKline, and Amgen. Before joining Resolian in 2015, Dr. Zhao served as Site Director of Preclinical Research at Amgen in Cambridge, Massachusetts, for over a decade. 

Currently, Dr. Zhao serves as an Adjunct Professor at the Eshelman School of Pharmacy of the University of North Carolina at Chapel Hill, North Carolina, and as Editor-in-Chief of Drug Metabolism & Bioanalysis Letters, a journal by Bentham Science, which publishes in all areas of drug metabolism and bioanalysis. Dr. Zhao received his Ph.D. degree in Medicinal Chemistry from Virginia Polytechnic and State University (popularly known as Virginia Tech) in Blacksburg, Virginia. 

 

Patrick Bennett

Chief Executive Officer

Linkedin

Patrick Bennett has over 35 years of experience in pharmaceutical analysis and laboratory management. Now Chief Business Officer at Resolian, Patrick’s experience includes the roles of Strategic Marketing Director for Pharma with Thermo Fisher Scientific, LabCorp, and Vice President of Strategy and Development with PPD. 

Patrick earned a B.S. degree in Toxicology and a M.S. degree in Pharmacology from the College of Pharmacy and Allied Health at St. John’s University and an M.B.A in International Marketing from the Martin J. Whitman School of Management at Syracuse University.